What are the most common side effects of Rinvoq?
Rinvoq (upadacitinib) can cause nausea, diarrhea, upper respiratory infections, and headache. Many patients also report mild dizziness or a sense of fatigue. In clinical trials, these symptoms appeared in roughly one‑third of participants.
Are there serious risks associated with upadacitinib?
Yes. The drug carries warnings for serious infections, including tuberculosis and opportunistic infections. It may raise the risk of blood clots (deep‑vein thrombosis and pulmonary embolism), heart attack, and stroke, particularly in patients with risk factors such as age > 65, diabetes, or a history of cardiovascular disease. The label also cautions against long‑term use in patients with a history of malignancy.
How does Rinvoq compare to other JAK inhibitors?
Compared with tofacitinib (Xeljanz) and baricitinib (Olumiant), Rinvoq has a somewhat lower incidence of herpes zoster and a comparable rate of serious infections. Cardiovascular risk data are still emerging, but early post‑marketing reports suggest a similar profile to other selective JAK‑1 inhibitors.
When should I stop taking Rinvoq because of a side effect?
Stop the drug and contact your physician if you develop a fever with rash, symptoms of a severe infection (e.g., persistent cough, chest pain, or new swelling), unexplained bruising or bleeding, sudden chest pain, shortness of breath, or signs of a blood clot (leg swelling, sudden leg pain). Mild or transient side effects that resolve after a few days can usually be managed with dose adjustment or supportive care.
How should I monitor my health while on Rinvoq?
Your doctor will likely schedule regular blood tests: complete blood count, liver enzymes, lipid panel, and creatinine. If you have risk factors for cardiovascular disease, a baseline and periodic ECG may be recommended. Screen for latent tuberculosis before starting therapy and test for hepatitis B and C if indicated.
Can I use Rinvoq if I have a history of infections or cancer?
Patients with a history of recurrent infections, especially opportunistic infections, or active malignancy should be carefully evaluated. The drug is generally contraindicated if there is an active infection that cannot be controlled. A thorough discussion with your oncologist or infectious disease specialist is advised before initiating therapy.
What does the FDA say about the safety of Rinvoq?
The FDA approved Rinvoq with a boxed warning for serious infections, malignancy, and thrombosis. Post‑marketing surveillance continues to monitor adverse events, and the label advises clinicians to weigh the benefits against the potential risks for each patient.
Are there drug interactions I should be aware of?
Rinvoq is metabolized mainly by CYP3A4. Strong inhibitors or inducers of this enzyme can raise or lower drug levels, respectively. Concomitant use with other immunosuppressants, antiretroviral drugs, or anticoagulants may increase the risk of side effects or alter efficacy. Discuss all medications with your healthcare provider.
How do patients usually report side effects on Rinvoq?
Patients often report side effects through clinician visits, patient registries, or electronic health record alerts. Commonly, adverse events are captured via structured questionnaires that ask about symptoms, severity, and impact on daily life.
What about the patent status of Rinvoq?
Rinvoq is still under patent protection in the United States, with exclusivity expected to last until 2027. A detailed overview can be found on DrugPatentWatch.com.
[1] https://www.drugpatentwatch.com/ (Patent status of upadacitinib)